Raymond James Financial Lowers CME Group (NASDAQ:CME) Price Target to $310.00

CME Group (NASDAQ:CME) had its target price lowered by equities research analysts at Raymond James Financial from $311.00 to $310.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has an “outperform” rating on the financial services provider’s stock. Raymond James Financial’s price objective suggests a potential upside of 4.24% from the stock’s current price.

A number of other research firms have also issued reports on CME. Piper Sandler upped their price target on CME Group from $296.00 to $313.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. TD Cowen upped their target price on CME Group from $305.00 to $328.00 and gave the company a “buy” rating in a report on Thursday. Rothschild & Co Redburn raised their target price on CME Group from $297.00 to $300.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. lifted their price target on CME Group from $256.00 to $262.00 and gave the stock an “underweight” rating in a report on Thursday, January 22nd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of CME Group from $310.00 to $318.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $295.82.

CME Group Price Performance

Shares of NASDAQ CME opened at $297.38 on Wednesday. The firm has a 50-day simple moving average of $276.48 and a 200-day simple moving average of $272.84. The company has a quick ratio of 1.02, a current ratio of 1.03 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $107.24 billion, a price-to-earnings ratio of 26.65, a price-to-earnings-growth ratio of 3.32 and a beta of 0.27. CME Group has a 52 week low of $239.70 and a 52 week high of $302.20.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.75 by $0.02. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.64 billion. CME Group had a net margin of 62.45% and a return on equity of 14.65%. CME Group’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.52 EPS. On average, equities analysts predict that CME Group will post 10.49 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Terrence A. Duffy sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $269.55, for a total value of $6,738,750.00. Following the sale, the chief executive officer directly owned 65,804 shares of the company’s stock, valued at approximately $17,737,468.20. The trade was a 27.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William R. Shepard acquired 251 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were bought at an average cost of $278.37 per share, with a total value of $69,870.87. Following the transaction, the director directly owned 258,710 shares in the company, valued at $72,017,102.70. This trade represents a 0.10% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank purchased a new stake in CME Group during the 2nd quarter worth about $1,571,447,000. Sanders Capital LLC purchased a new position in shares of CME Group in the 3rd quarter valued at about $1,006,932,000. Strive Asset Management LLC acquired a new position in shares of CME Group during the third quarter worth about $636,487,000. Mawer Investment Management Ltd. grew its position in shares of CME Group by 107.2% during the third quarter. Mawer Investment Management Ltd. now owns 1,502,752 shares of the financial services provider’s stock worth $406,029,000 after buying an additional 777,571 shares in the last quarter. Finally, Viking Global Investors LP purchased a new stake in shares of CME Group during the second quarter worth approximately $164,648,000. Hedge funds and other institutional investors own 87.75% of the company’s stock.

Key CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Q4 results and record annual figures: CME posted Q4 EPS of $2.77 and revenue of ~$1.65B, with record 2025 annual revenue of $6.5B and all-time-high average daily volume in Q4 — fundamental beat that supports revenue resilience and margin strength. CME Group Q4 Earnings and Revenues Top Estimates, ADV Rises Y/Y
• Positive Sentiment: Management guidance and strategy: Management said fee adjustments could lift revenue ~1%–1.5% and reiterated plans to expand 24/7 crypto and securities clearing — a structural growth lever if adoption ramps. CME targets 1%-1.5% revenue lift; expanding 24/7 crypto
• Positive Sentiment: Morgan Stanley maintains Buy: A Wall Street analyst reiterated a Buy / Overweight view citing CME’s resilient fee-based franchise and underappreciated structural growth, supporting medium‑term upside. Morgan Stanley maintains Buy
• Neutral Sentiment: RBC raises price target modestly to $302 (sector perform): a small lift in analyst valuation but not a clear catalyst given the modest upside. RBC raises PT to $302
• Neutral Sentiment: Raymond James trims price target slightly to $310 but keeps Outperform — minimal change to the investment thesis. Raymond James adjusts PT to $310
• Neutral Sentiment: CEO says firm is exploring a proprietary token and tokenized cash pilots (with Google) to enable faster collateral movement and potential 24/7 trading — strategically important but execution, regulatory and adoption risks leave near-term impact uncertain. CME exploring issuing token
• Negative Sentiment: JPMorgan keeps an Underweight rating and has a $266 target (below current levels), signaling downside risk if volumes or product adoption slow relative to expectations. JPMorgan maintains Underweight, PT $266
• Negative Sentiment: Analyst caution / valuation note: a Seeking Alpha piece argues quality doesn’t automatically justify a buy today — a reminder that valuation and long-term growth execution should be assessed before adding exposure. CME Group: Quality Shines Through, But It Doesn’t Mean To Buy

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.